In developing new COALITION implants, how should Globus Medical weigh the benefits of increased fusion rates against potential risks of adjacent segment degeneration?

Introduction

The development of new COALITION implants presents Globus Medical with a critical trade-off between increased fusion rates and potential risks of adjacent segment degeneration. This scenario encapsulates the delicate balance between enhancing product efficacy and ensuring long-term patient safety. I'll analyze this trade-off by examining the product context, identifying key metrics, designing experiments, and providing a data-driven recommendation.

Step 1

Clarifying Questions (3 minutes)

• Context: Based on the current market landscape, I'm thinking COALITION implants are a significant innovation. Could you provide more context on how these implants fit into our product portfolio and competitive positioning?

Why it matters: Helps understand the strategic importance of this product line Expected answer: COALITION implants are a key growth driver in our spinal fusion segment Impact on approach: Would influence resource allocation and risk tolerance in development

• Business Context: Considering our revenue model, I assume these implants contribute significantly to our bottom line. How do COALITION implants align with our current business goals and revenue targets?

Why it matters: Clarifies the financial stakes involved in this decision Expected answer: COALITION implants are expected to drive 20% of spinal fusion revenue Impact on approach: Would affect the urgency of development and market introduction

• User Impact: I'm thinking about the patient journey here. Can you help me understand which patient segments are most affected by this trade-off between fusion rates and adjacent segment degeneration?

Why it matters: Identifies the primary beneficiaries and potential risk groups Expected answer: Primarily affects patients with degenerative disc disease in multiple segments Impact on approach: Would guide targeted development and risk mitigation strategies

• Technical: Given the complexity of spinal implants, I'm curious about the technical feasibility of modifying the implant design. What's our current capability to iterate on the COALITION implant design to address both fusion rates and adjacent segment concerns?

Why it matters: Assesses our ability to innovate within technical constraints Expected answer: We have advanced 3D printing capabilities for rapid prototyping Impact on approach: Would influence the scope and timeline of potential design modifications

• Timeline: Considering the potential impact on patient outcomes, I'm wondering about the urgency of this decision. What's our timeline for finalizing the COALITION implant design and bringing it to market?

Why it matters: Helps balance thoroughness of research with market pressures Expected answer: Aiming for FDA submission in 18 months Impact on approach: Would determine the depth of testing and iteration cycles possible